{
  "ticker": "DNLI",
  "company_name": "Denali Therapeutics Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05842941",
      "title": "HEALEY ALS Platform Trial - Regimen G DNL343",
      "status": "COMPLETED",
      "phase": "PHASE2, PHASE3",
      "condition": "Amyotrophic Lateral Sclerosis",
      "start_date": "2023-05-24",
      "completion_date": "2024-10-29",
      "enrollment": 0,
      "sponsor": "Merit E. Cudkowicz, MD"
    },
    {
      "nct_id": "NCT05262023",
      "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Frontotemporal Dementia",
      "start_date": "2022-02-01",
      "completion_date": "2028-11",
      "enrollment": 0,
      "sponsor": "Denali Therapeutics Inc."
    },
    {
      "nct_id": "NCT06075537",
      "title": "An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007",
      "status": "ENROLLING_BY_INVITATION",
      "phase": "PHASE2, PHASE3",
      "condition": "Mucopolysaccharidosis II",
      "start_date": "2023-09-20",
      "completion_date": "2027-06",
      "enrollment": 0,
      "sponsor": "Denali Therapeutics Inc."
    },
    {
      "nct_id": "NCT06281158",
      "title": "A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Volunteers",
      "start_date": "2024-03-01",
      "completion_date": "2024-04-30",
      "enrollment": 0,
      "sponsor": "Denali Therapeutics Inc."
    },
    {
      "nct_id": "NCT05006352",
      "title": "A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Amyotrophic Lateral Sclerosis",
      "start_date": "2021-08-11",
      "completion_date": "2024-06-05",
      "enrollment": 0,
      "sponsor": "Denali Therapeutics Inc."
    },
    {
      "nct_id": "NCT05005338",
      "title": "A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Volunteers",
      "start_date": "2021-07-28",
      "completion_date": "2021-09-23",
      "enrollment": 0,
      "sponsor": "Biogen"
    },
    {
      "nct_id": "NCT05371613",
      "title": "A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)",
      "status": "RECRUITING",
      "phase": "PHASE2, PHASE3",
      "condition": "Mucopolysaccharidosis II",
      "start_date": "2022-07-21",
      "completion_date": "2027-12",
      "enrollment": 0,
      "sponsor": "Denali Therapeutics Inc."
    },
    {
      "nct_id": "NCT04581772",
      "title": "A Study to Evaluate the Bioavailability and Safety of DNL343 in Healthy Volunteers",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Volunteers",
      "start_date": "2020-12-23",
      "completion_date": "2021-06-04",
      "enrollment": 0,
      "sponsor": "Denali Therapeutics Inc."
    },
    {
      "nct_id": "NCT03757325",
      "title": "Study to Evaluate DNL747 in Subjects With Alzheimer's Disease",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Alzheimer Disease",
      "start_date": "2019-02-13",
      "completion_date": "2019-12-05",
      "enrollment": 0,
      "sponsor": "Denali Therapeutics Inc."
    },
    {
      "nct_id": "NCT03710707",
      "title": "Study to Evaluate DNL201 in Subjects With Parkinson's Disease",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Parkinson Disease",
      "start_date": "2018-12-04",
      "completion_date": "2019-12-06",
      "enrollment": 0,
      "sponsor": "Denali Therapeutics Inc."
    }
  ],
  "summary": {
    "total_trials": 25,
    "by_phase": {
      "PHASE2, PHASE3": 3,
      "PHASE1, PHASE2": 3,
      "PHASE1": 14,
      "PHASE2": 2,
      "PHASE3": 1,
      "": 2
    },
    "by_status": {
      "COMPLETED": 14,
      "ACTIVE_NOT_RECRUITING": 4,
      "ENROLLING_BY_INVITATION": 1,
      "RECRUITING": 2,
      "TERMINATED": 2,
      "NOT_YET_RECRUITING": 2
    },
    "active_trials": 7,
    "completed_trials": 14,
    "conditions": [
      "Alzheimer Disease",
      "Alzheimer Disease, Early Onset",
      "Amyotrophic Lateral Sclerosis",
      "Frontotemporal Dementia",
      "Healthy Participant",
      "Healthy Volunteers",
      "Late-onset Pompe Disease",
      "Mucopolysaccharidosis II",
      "Mucopolysaccharidosis III-A",
      "Mucopolysaccharidosis Type IIIA",
      "Parkinson Disease"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:17:59.098224",
    "search_query": "Denali Therapeutics Inc.",
    "url": "https://clinicaltrials.gov/search?term=Denali+Therapeutics+Inc."
  }
}